{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:19:15Z","timestamp":1782321555595,"version":"3.54.5"},"reference-count":76,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.clml.2023.05.014","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T21:18:19Z","timestamp":1686863899000},"page":"e253-e259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Plasmablastic Lymphoma: Past, Present, and Future"],"prefix":"10.1016","volume":"23","author":[{"given":"Supreet","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudarsan","family":"Kollimuttathuillam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clml.2023.05.014_bib0001","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","article-title":"Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection","volume":"89","author":"Delecluse","year":"1997","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2023.05.014_bib0002","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/annonc\/mdw684","article-title":"Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group","volume":"28","author":"Tchernonog","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.05.014_bib0003","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/10428190400007789","article-title":"Oral cavity lymphomas in immunocompetent and human immunodeficiency virus infected patients","volume":"46","author":"Cattaneo","year":"2005","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.clml.2023.05.014_bib0004","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1473-3099(08)70067-7","article-title":"Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection","volume":"8","author":"Riedel","year":"2008","journal-title":"Lancet Infect Dis"},{"issue":"27","key":"10.1016\/j.clml.2023.05.014_bib0005","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.3748\/wjg.14.4395","article-title":"AIDS-associated plasmablastic lymphoma presenting as a poorly differentiated esophageal tumor: a diagnostic dilemma","volume":"14","author":"Mani","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.clml.2023.05.014_bib0006","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1007\/s12032-011-9930-z","article-title":"Unusual presentation of gastric plasmablastic lymphoma in HIV-negative patient","volume":"29","author":"Mihaljevic","year":"2012","journal-title":"Med Oncol"},{"issue":"11","key":"10.1016\/j.clml.2023.05.014_bib0007","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/pin.12005","article-title":"Plasmablastic lymphoma of the stomach in an HIV-negative patient","volume":"62","author":"Hashimoto","year":"2012","journal-title":"Pathol Int"},{"issue":"3","key":"10.1016\/j.clml.2023.05.014_bib0008","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4321\/S1130-01082013000300008","article-title":"Gastric plasmablastic lymphoma in HIV-negative patient","volume":"105","author":"Marques","year":"2013","journal-title":"Rev Esp Enferm Dig"},{"issue":"1","key":"10.1016\/j.clml.2023.05.014_bib0009","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.anndiagpath.2010.11.002","article-title":"Ikpatt O. Extraoral plasmablastic lymphoma with intravascular component and MYC translocation","volume":"16","author":"Chapman-Fredricks","year":"2012","journal-title":"Ann Diagn Pathol"},{"issue":"3","key":"10.1016\/j.clml.2023.05.014_bib0010","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3346\/jkms.2010.25.3.496","article-title":"A case report with plasmablastic lymphoma of the jejunum","volume":"25","author":"Cha","year":"2010","journal-title":"J Korean Med Sci"},{"issue":"10","key":"10.1016\/j.clml.2023.05.014_bib0011","first-page":"669","article-title":"Plasmablastic Lymphoma presenting as small intestinal polyposis: a case-report","volume":"14","author":"Bahari","year":"2012","journal-title":"Iran Red Crescent Med J"},{"issue":"24","key":"10.1016\/j.clml.2023.05.014_bib0012","doi-asserted-by":"crossref","first-page":"7598","DOI":"10.3748\/wjg.v21.i24.7598","article-title":"Case of plasmablastic lymphoma of the sigmoid colon and literature review","volume":"21","author":"Haramura","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clml.2023.05.014_bib0013","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1752-1947-5-168","article-title":"Plasmablastic lymphoma in the ano-rectal junction presenting in an immunocompetent man: a case report","volume":"5","author":"Brahmania","year":"2011","journal-title":"J Med Case Rep"},{"issue":"33","key":"10.1016\/j.clml.2023.05.014_bib0014","doi-asserted-by":"crossref","first-page":"11894","DOI":"10.3748\/wjg.v20.i33.11894","article-title":"Manifestations of gastrointestinal plasmablastic lymphoma: a case series with literature review","volume":"20","author":"Luria","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.clml.2023.05.014_bib0015","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1159\/000503586","article-title":"An endotracheal plasmablastic lymphoma","volume":"98","author":"Bots","year":"2019","journal-title":"Respiration"},{"key":"10.1016\/j.clml.2023.05.014_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-225374","article-title":"Plasmablastic lymphoma masquerading solitary plasmacytoma in an immunocompetent patient","volume":"2018","author":"Diaz","year":"2018","journal-title":"BMJ Case Rep"},{"issue":"1","key":"10.1016\/j.clml.2023.05.014_bib0017","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13000-017-0672-x","article-title":"Unusual presentation of plasmablastic lymphoma involving ovarian mature cystic teratoma: a case report","volume":"12","author":"Had\u017eisejdi\u0107","year":"2017","journal-title":"Diagn Pathol"},{"issue":"3","key":"10.1016\/j.clml.2023.05.014_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-226755","article-title":"Primary central nervous system plasmablastic lymphoma in an HIV-positive patient","volume":"12","author":"Rhoades","year":"2019","journal-title":"BMJ Case Rep"},{"issue":"4","key":"10.1016\/j.clml.2023.05.014_bib0019","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/hupa.2002.124723","article-title":"AIDS-related non-Hodgkin's lymphomas: from pathology and molecular pathogenesis to treatment","volume":"33","author":"Carbone","year":"2002","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1016\/j.clml.2023.05.014_bib0020","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/01.pas.0000126781.87158.e3","article-title":"Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities","volume":"28","author":"Colomo","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.clml.2023.05.014_bib0021","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/TP.0b013e318242162d","article-title":"Plasmablastic post-transplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry","volume":"93","author":"Zimmermann","year":"2012","journal-title":"Transplantation"},{"issue":"19","key":"10.1016\/j.clml.2023.05.014_bib0022","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.05.014_bib0023","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/modpathol.2016.162","article-title":"Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1","volume":"30","author":"Montes-Moreno","year":"2017","journal-title":"Mod Pathol"},{"issue":"11","key":"10.1016\/j.clml.2023.05.014_bib0024","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1038\/leu.2015.109","article-title":"Gene expression analysis of plasmablastic lymphoma identifies downregulation of B-cell receptor signaling and additional unique transcriptional programs","volume":"29","author":"Chapman","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2023.05.014_bib0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1158\/2643-3249.BCD-20-0075","article-title":"The genomic landscape of HIV-associated plasmablastic lymphoma","volume":"1","author":"K\u00fcppers","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"10.1016\/j.clml.2023.05.014_bib0026","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.V95.4.1406.004k26_1406_1412","article-title":"HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma","volume":"95","author":"Dupin","year":"2000","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.05.014_bib0027","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00000478-200401000-00003","article-title":"Oral plasmablastic lymphomas in AIDS patients are associated with human herpesvirus 8","volume":"28","author":"Cioc","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.clml.2023.05.014_bib0028","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/his.13959","article-title":"High incidence of MYC rearrangement in human immunodeficiency virus-positive plasmablastic lymphoma","volume":"76","author":"Miao","year":"2020","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.clml.2023.05.014_bib0029","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2643-3230.BCD-20-0051","article-title":"Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway","volume":"1","author":"Liu","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"10.1016\/j.clml.2023.05.014_bib0030","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3324\/haematol.2020.251579","article-title":"Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma","volume":"106","author":"Garcia-Reyero","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.clml.2023.05.014_bib0031","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1038\/bcj.2015.24","article-title":"BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis","volume":"5","author":"Rustad","year":"2015","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.clml.2023.05.014_bib0032","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/bloodadvances.2021005486","article-title":"Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways","volume":"6","author":"Witte","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.clml.2023.05.014_bib0033","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.3324\/haematol.2020.271957","article-title":"MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma","volume":"106","author":"Ramis-Zaldivar","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.clml.2023.05.014_bib0034","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3892\/or.2015.3808","article-title":"Human immunodeficiency virus-negative plasmablastic lymphoma: a comprehensive analysis of 114 cases","volume":"33","author":"Liu","year":"2015","journal-title":"Oncol Rep"},{"issue":"4","key":"10.1016\/j.clml.2023.05.014_bib0035","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2141.2010.08159.x","article-title":"Advances in the understanding of MYC-induced lymphomagenesis","volume":"149","author":"Klapproth","year":"2010","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.clml.2023.05.014_bib0036","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ajh.21250","article-title":"HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases","volume":"83","author":"Castillo","year":"2008","journal-title":"Am J Hematol"},{"issue":"15","key":"10.1016\/j.clml.2023.05.014_bib0037","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1182\/blood-2014-10-567479","article-title":"The biology and treatment of plasmablastic lymphoma","volume":"125","author":"Castillo","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2023.05.014_bib0038","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.3109\/10428194.2010.516040","article-title":"Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma","volume":"51","author":"Castillo","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.clml.2023.05.014_bib0039","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/ajh.25955","article-title":"Survival analysis in treated plasmablastic lymphoma patients: a population-based study","volume":"95","author":"Florindez","year":"2020","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2023.05.014_bib0040","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-015-0163-z","article-title":"Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients","volume":"8","author":"Loghavi","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.clml.2023.05.014_bib0041","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/PAS.0000000000000234","article-title":"Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases","volume":"38","author":"Morscio","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.clml.2023.05.014_bib0042","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1097\/PAS.0b013e3181f3e29f","article-title":"IG\/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas","volume":"34","author":"Valera","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.clml.2023.05.014_bib0043","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood.2019003959","article-title":"Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)","volume":"136","author":"Ramos","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.05.014_bib0044","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/QAD.0b013e32835e069d","article-title":"Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study","volume":"27","author":"Schommers","year":"2013","journal-title":"Aids"},{"issue":"1","key":"10.1016\/j.clml.2023.05.014_bib0045","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/10428194.2014.911867","article-title":"Plasmablastic lymphoma among human immunodeficiency virus-positive patients: results of a single center's experience","volume":"56","author":"Cattaneo","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2023.05.014_bib0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-134972","article-title":"Survival outcomes for plasmablastic lymphoma: an international, multicentre study by the Australasian lymphoma alliance","volume":"136","author":"Di Ciaccio","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2023.05.014_bib0047","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.bbmt.2015.03.008","article-title":"Autologous hematopoietic stem cell transplantation for plasmablastic lymphoma: the European Society for Blood and Marrow Transplantation experience","volume":"21","author":"Cattaneo","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.clml.2023.05.014_bib0048","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.clml.2011.03.008","article-title":"HIV-negative plasmablastic lymphoma: not in the mouth","volume":"11","author":"Castillo","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.clml.2023.05.014_bib0049","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3109\/10428194.2015.1113281","article-title":"Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium","volume":"57","author":"Noy","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"10.1016\/j.clml.2023.05.014_bib0050","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1182\/blood-2013-04-498964","article-title":"Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients","volume":"122","author":"Barta","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2023.05.014_bib0051","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjh.15156","article-title":"Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma","volume":"184","author":"Castillo","year":"2019","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.clml.2023.05.014_bib0052","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/sj.leu.2403460","article-title":"Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas","volume":"18","author":"An","year":"2004","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2023.05.014_bib0053","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1080\/10428194.2017.1416365","article-title":"Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis","volume":"59","author":"Dittus","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2023.05.014_bib0054","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1658-3876(10)50050-5","article-title":"A meta-analysis of highly active anti-retroviral therapy for treatment of plasmablastic lymphoma","volume":"3","author":"Guan","year":"2010","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"7","key":"10.1016\/j.clml.2023.05.014_bib0055","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.joms.2005.12.039","article-title":"Spontaneous regression of an HIV-associated plasmablastic lymphoma in the oral cavity: a case report","volume":"65","author":"Armstrong","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"issue":"2","key":"10.1016\/j.clml.2023.05.014_bib0056","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/10428190290006260","article-title":"Udden MM. Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy","volume":"43","author":"Nasta","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.clml.2023.05.014_bib0057","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3324\/haematol.2018.211904","article-title":"Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens","volume":"105","author":"Vidal-Crespo","year":"2020","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2023.05.014_bib0058","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1182\/blood-2021-150800","article-title":"Daratumumab plus chemotherapy induces complete responses in a consecutive series of four patients with plasmablastic lymphoma","volume":"138","author":"Ricker","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.05.014_bib0059","doi-asserted-by":"crossref","first-page":"S275","DOI":"10.1016\/S2152-2650(20)30893-4","article-title":"ABCL-407: daratumumab, lenalidomide, and dexamethasone (DRD), an active regimen in the treatment of sirolimus-associated plasmablastic lymphoma (PBL) in the setting of Gorham's lymphangiomatosis: a case report","volume":"20","author":"Lee","year":"2020","journal-title":"Clin Lymphom Myelom Leukem"},{"issue":"8","key":"10.1016\/j.clml.2023.05.014_bib0060","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3324\/haematol.2016.141978","article-title":"Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients","volume":"101","author":"Laurent","year":"2016","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.clml.2023.05.014_bib0061","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1486950","article-title":"EBV infection determines the immune hallmarks of plasmablastic lymphoma","volume":"7","author":"Gravelle","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clml.2023.05.014_bib0062","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.702593","article-title":"Case report: successful management of a refractory plasmablastic lymphoma patient with tislelizumab and lenalidomide","volume":"12","author":"Cheng","year":"2021","journal-title":"Front Immunol."},{"issue":"10","key":"10.1016\/j.clml.2023.05.014_bib0063","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1016\/j.clml.2019.06.008","article-title":"Therapeutic potential of checkpoint inhibitors in refractory plasmablastic lymphoma","volume":"19","author":"Damlaj","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2023.05.014_bib0064","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.anndiagpath.2005.07.009","article-title":"Plasmablastic lymphoma: a clinicopathologic correlation","volume":"10","author":"Folk","year":"2006","journal-title":"Ann Diagn Pathol"},{"issue":"12","key":"10.1016\/j.clml.2023.05.014_bib0065","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1200\/JCO.2012.46.9593","article-title":"Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia","volume":"31","author":"Holderness","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2023.05.014_bib0066","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s00277-016-2732-9","article-title":"Plasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settings","volume":"95","author":"Yanamandra","year":"2016","journal-title":"Ann Hematol"},{"issue":"1-2","key":"10.1016\/j.clml.2023.05.014_bib0067","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000455146","article-title":"A case of plasmablastic lymphoma achieving complete response and durable remission after lenalidomide-based therapy","volume":"40","author":"Schmit","year":"2017","journal-title":"Oncol Res Treat"},{"issue":"23","key":"10.1016\/j.clml.2023.05.014_bib0068","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clml.2023.05.014_bib0069","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-Cell lymphoma","volume":"386","author":"Locke","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2023.05.014_bib0070","first-page":"1100","article-title":"High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease","volume":"89","author":"Gabarre","year":"2004","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.clml.2023.05.014_bib0071","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2004-04-1532","article-title":"Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas","volume":"105","author":"Krishnan","year":"2005","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2023.05.014_bib0072","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.bbmt.2014.06.009","article-title":"Hematopoietic cell transplantation for plasmablastic lymphoma: a review","volume":"20","author":"Al-Malki","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.clml.2023.05.014_bib0073","doi-asserted-by":"crossref","first-page":"e24498","DOI":"10.1097\/MD.0000000000024498","article-title":"Allogeneic hematopoietic stem cell transplantation in a patient with HIV-negative recurrent plasmablastic lymphoma: a case report","volume":"100","author":"Rong","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.clml.2023.05.014_bib0074","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/10428194.2021.1986218","article-title":"Plasmablastic lymphomas show restricted EBV latency profile and MYCgene aberrations","volume":"63","author":"Ramburan","year":"2022","journal-title":"Leuk Lymphoma."},{"issue":"1","key":"10.1016\/j.clml.2023.05.014_bib0075","doi-asserted-by":"crossref","first-page":"E28","DOI":"10.1002\/ajh.25682","article-title":"Axicabtagene ciloleucel for CD19+ plasmablastic lymphoma","volume":"95","author":"Raychaudhuri","year":"2020","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2023.05.014_bib0076","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006684","article-title":"BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma","volume":"11","author":"Raghunandan","year":"2023","journal-title":"J ImmunoTher Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:23Z","timestamp":1761871343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023001817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":76,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2152265023001817"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.05.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasmablastic Lymphoma: Past, Present, and Future","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}